Patents by Inventor Eberhard Spanuth

Eberhard Spanuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230030564
    Abstract: The present invention concerns methods for aiding in the risk assessment of a patient with suspected sepsis. For example, the risk of poor outcome (such as of a complicated clinical course and/or of mortality) can be assessed. The methods of the present invention may comprise the steps of (a) determining the amount of the biomarker Presepsin in a sample from a patient with suspected sepsis who has a known qSOFA (quick Sequential Organ Failure-Assessment) score of 0, 1, 2 or 3, (b) determining the amount of the biomarker Pro-calcitonin (PCT) in a sample from the patient, comparing the amounts determined in steps (b) and (c) to reference amounts, and (d) aiding in the risk assessment of a patient with suspected sepsis. The methods of the present invention may be computer-implemented.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 2, 2023
    Inventors: Andrea Horsch, Eberhard Spanuth
  • Patent number: 11041864
    Abstract: Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: June 22, 2021
    Assignees: LSI MEDIENCE CORPORATION, MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Matsuya, Yoshikazu Okamura, Ralf Thomae, Eberhard Spanuth, Boris Ivandic, Kamon Shirakawa, Shigeatsu Endo
  • Publication number: 20190257841
    Abstract: The present invention relates to a method for diagnosis of a cardiovascular disease or condition or atherosclerosis and for a method for evaluating the risk of a subject of developing the same. Methods are further provided for evaluating a subject's risk of mortality, for evaluating whether a subject will benefit from a certain treatment or whether a subject needs to be hospitalized or whether a subject may be discharged. The present invention provides sCD14 or a fragment or derivative thereof (including in particular sCD14-ST) as a novel marker for cardiovascular risk in general, more specifically as a marker for cardiovascular disease or condition, or atherosclerosis.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 22, 2019
    Applicant: LSI MEDIENCE CORPORATION
    Inventor: Eberhard SPANUTH
  • Publication number: 20150346217
    Abstract: The present invention relates to a method for diagnosis of a cardiovascular disease or condition or atherosclerosis and for a method for evaluating the risk of a subject of developing the same. Methods are further provided for evaluating a subject's risk of mortality, for evaluating whether a subject will benefit from a certain treatment or whether a subject needs to be hospitalized or whether a subject may be discharged. The present invention provides sCD14 or a fragment or derivative thereof (including in particular sCD14-ST) as a novel marker for cardiovascular risk in general, more specifically as a marker for cardiovascular disease or condition, or atherosclerosis.
    Type: Application
    Filed: December 27, 2013
    Publication date: December 3, 2015
    Applicant: LSI MEDIENCE CORPORATION
    Inventor: Eberhard SPANUTH
  • Publication number: 20130288276
    Abstract: Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.
    Type: Application
    Filed: January 10, 2012
    Publication date: October 31, 2013
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., Mitsubishi Chemical Medience Corporation
    Inventors: Takeshi Matsuya, Yoshikazu Okamura, Ralf Thomae, Eberhard Spanuth, Boris Ivandic, Kamon Shirakawa, Shigeatsu Endo
  • Publication number: 20130236916
    Abstract: The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.
    Type: Application
    Filed: April 24, 2013
    Publication date: September 12, 2013
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Eberhard Spanuth, Boris Ivandic
  • Patent number: 8444932
    Abstract: The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: May 21, 2013
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Eberhard Spanuth, Boris Ivandic
  • Patent number: 8062896
    Abstract: The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitor, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor and further provides methods for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: November 22, 2011
    Assignee: Roche Diagnostics Operations, Inc.
    Inventor: Eberhard Spanuth
  • Publication number: 20110129936
    Abstract: The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.
    Type: Application
    Filed: February 3, 2011
    Publication date: June 2, 2011
    Inventors: Eberhard Spanuth, Boris Ivandic
  • Publication number: 20100261284
    Abstract: Described is a method of identifying if a subject is to be admitted to the hospital or intensive care unit, the method comprising a) determining the amount of GDF 15 in a sample of the subject, and b) comparing the amount of GDF 15 determined in step a) to a reference amount, whereby a subject to be admitted to the hospital or intensive care unit is to be identified. Also described is a method for predicting the risk of mortality based on determining the amount of GDF 15 in a subject. Also described are devices and kits for carrying out the aforementioned methods.
    Type: Application
    Filed: June 24, 2010
    Publication date: October 14, 2010
    Inventor: Eberhard Spanuth
  • Patent number: 7790397
    Abstract: The present invention concerns methods for diagnosing myocardial infarction, for performing risk stratification of myocardial infarction, for making a prognosis of a disease course in a myocardial infarction patient, for identifying a patient with elevated risk of myocardial infarction, or combinations thereof, wherein a determination of at least three markers is performed on a patient sample. Furthermore, kits for performing the methods are provided.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: September 7, 2010
    Assignee: Roche Diagnostics, Corporation
    Inventors: Christian Hamm, Eberhard Spanuth
  • Publication number: 20100173321
    Abstract: The present invention concerns methods for diagnosing myocardial infarction, for performing risk stratification of myocardial infarction, for making a prognosis of a disease course in a myocardial infarction patient, for identifying a patient with elevated risk of myocardial infarction, or combinations thereof, wherein a determination of at least three markers is performed on a patient sample. Furthermore, kits for performing the methods are provided.
    Type: Application
    Filed: May 14, 2003
    Publication date: July 8, 2010
    Inventors: Christian Hamm, Eberhard Spanuth
  • Publication number: 20090023591
    Abstract: The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitor, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP.
    Type: Application
    Filed: September 2, 2008
    Publication date: January 22, 2009
    Inventor: Eberhard Spanuth
  • Patent number: 7432107
    Abstract: The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for adminitstration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitior, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: October 7, 2008
    Assignee: Roche Diagnostics Operations, Inc.
    Inventor: Eberhard Spanuth
  • Publication number: 20060234300
    Abstract: The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for adminitstration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitior, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP.
    Type: Application
    Filed: December 8, 2005
    Publication date: October 19, 2006
    Inventor: Eberhard Spanuth
  • Publication number: 20060166303
    Abstract: The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective Cox-2 inhibitor, comprising the steps of a) measuring, preferably in vitro, the level of a cardiac hormone, b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP.
    Type: Application
    Filed: January 24, 2005
    Publication date: July 27, 2006
    Inventor: Eberhard Spanuth